The Journal. Trillion Dollar Shot, Episode 4: The Disruptors
11 snips
Jun 9, 2024 In this engaging discussion, David Ricks, CEO of Eli Lilly and a pioneer in diabetes and weight-loss medications, delves into the transformative impact of GLP-1 drugs like Ozempic. He highlights the potential for 9% of Americans using these medications by 2030 and discusses the company's skyrocketing revenue from innovative treatments. Ricks also explores how these drugs could revolutionize addiction treatment and disrupt various industries, reshaping health and consumer behavior for years to come.
AI Snips
Chapters
Transcript
Episode notes
Mounjaro vs. Prozac
- Eli Lilly's CEO, Dave Ricks, compared Mounjaro's success to Prozac's in the late 80s.
- Both drugs addressed previously unmet needs, offering solutions where lifestyle changes were the only option.
Missed Opportunity
- Eli Lilly did not capitalize on Prozac's success by developing new drugs based on the same science.
- After the patent expired, they lost market share to generics, a mistake they hope to avoid with Mounjaro.
Retitrutide: The Next Big Thing?
- Eli Lilly is developing retitrutide, a new drug mimicking three hormones, potentially surpassing Mounjaro in weight loss efficacy.
- It targets visceral fat and liver obesity, aiming to achieve greater weight reduction than Mounjaro's 21% average.